Heidelberg Pharma to Participate and Present at Upcoming Leading Scientific Conferences in May and June 2024

Heidelberg Pharma AG, a clinical-stage biotech company specializing in Antibody Drug Conjugates (ADCs), has announced participation in several prestigious scientific conferences scheduled for May and June 2024. The company aims to present its innovative ADC technology platforms and latest developments in cancer treatment.

The company will feature prominently at the 10th Annual Oncology Innovation Forum on May 31 in Chicago. CEO Professor Andreas Pahl will be part of a panel discussion on NextGen ADC investment and will also deliver a company presentation.

Additionally, Heidelberg Pharma's leaders will attend the ASCO Annual Meeting in Chicago and the BIO International Convention in San Diego, both in early June. The Jefferies Global Healthcare Conference in New York will also see their active involvement.

These conferences provide an opportunity for the company to showcase HDP-101, its Amanitin-based ADC product candidate for multiple myeloma, which is in Phase I/IIa trials. Further details and opportunities for meetings can be arranged through the respective conference systems.